PatentJul 1, 2026, 08:11 AM
Allarity Therapeutics Secures Key U.S. Patent for Stenoparib DRP®
AI Summary
Allarity Therapeutics announced that the United States Patent and Trademark Office (USPTO) has granted a key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, providing exclusivity until April 2042. This strengthens the company's intellectual property foundation for its lead oncology asset. Additionally, at its annual meeting, stockholders approved the election of a director, ratification of the auditor, an increase in the equity incentive plan, advisory executive compensation, and the issuance of common stock under a purchase agreement. A proposal to limit officer liability did not pass.
Key Highlights
- USPTO granted key U.S. patent for Allarity's stenoparib-specific DRP® companion diagnostic.
- The patent provides exclusivity for stenoparib with the DRP® in the U.S. until April 2042.
- Allarity Therapeutics held its Annual Meeting on June 26, 2026, with 54.10% of shares present.
- Jesper Hoiland was elected as director for an annual term expiring in 2029.
- Appointment of Wolf & Company, P.C. as independent auditor for 2026 was ratified.
- Equity Incentive Plan amended to increase authorized shares from 1,521,990 to 2,021,990.
- Issuance of common stock to Tumim Stone Capital LLC in excess of the Exchange Cap was approved.
- A proposal to amend the Certificate of Incorporation to limit officer liability did not pass.
Price Impact
More from ALLR